US FDA’s Genetic Metabolic Diseases Adcomm Debuts With Zevra’s Arimoclomol

 
• By Sue Sutter

The new panel’s inaugural 2 August meeting will take up a challenging drug application, currently in its second review cycle, for Niemann-Pick disease type C, an ultra-rare condition without approved therapeutics.

Stage
The Genetic Metabolic Diseases Adcomm is scheduled for its first meeting on 2 August, although the committee's standing members have not yet been announced. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers